Euroopan unioni - islanti - EMA (European Medicines Agency)

ge healthcare as - perflutren - hjartavöðvun - andstæður frá miðöldum - Þetta lyf er eingöngu ætlað til greiningar. optison er transpulmonary hjartaómunar andstæða umboðsmaður til að nota í grunaðir eða komið hjarta sjúkdómur til að veita ógegnsæi hjarta chambers, auka vinstri-op-hjartaþelshöfnun-landamæri uppdrætti með leiðir framför í vegg-hreyfing visualisation. optison skal aðeins notaður í sjúklingar þar rannsókn án andstæða aukahlutur er ófullnægjandi.

Euroopan unioni - islanti - EMA (European Medicines Agency)

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Euroopan unioni - islanti - EMA (European Medicines Agency)

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - Ónæmisörvandi, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

Euroopan unioni - islanti - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - sugammadex sodium - taugakerfi - Öll önnur lækningavörur - afturköllun taugavöðvablokkunar sem valdið er af rócuronium eða vecuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

boehringer ingelheim international gmbh* - tiotropii bromidum inn - innöndunarlausn - 2,5 míkróg/skammt

Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

boehringer ingelheim international gmbh* - tiotropii bromidum inn - innöndunarduft, hart hylki - 18 míkróg/hylki

Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - paclitaxelum inn - innrennslisþykkni, lausn - 6 mg/ml

Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - tiotropii bromidum inn - innöndunarduft, hart hylki - 10 míkróg

Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

medac gesellschaft für klinische spezialpräparate gmbh - doxorubicinum hýdróklóríð - innrennslislyf, lausn - 2 mg/ml

Islanti - islanti - LYFJASTOFNUN (Icelandic Medicines Agency)

accord healthcare b.v. - mycophenolatum natríum - magasýruþolin tafla - 180 mg